Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that the company's SynCon™ H1N1 influenza DNA vaccines achieved protective antibody responses against H1N1 swine influenza virus (A/Swine/Iowa/35233/1999) in 100% of pigs immunized with a two-dose vaccine regimen.